Stockreport

MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF MSD reported Q4 global sales of $16.4bn, a 5% increase from the same period in 2024. Full-year sales in 2025 grew 1% to reach $65bn. While year-end results outperform [Read more]